The invention discloses a novel reverse-osmosis scale inhibitor which comprises the following raw materials in parts by weight: 2-8 parts of sodium citrate, 33-45 parts of hydrolytic polymaleic anhydride, 28-37 parts of polyepoxysuccinic acid salt, 9-15 parts of urotropine, 13-20 parts of polylactic acid, and 40-50 parts of water. A preparation method comprises the following steps: adding sodium citrate, hydrolytic polymaleic anhydride, polyepoxysuccinic acid salt, urotropine and half of water into a reaction kettle, heating to 40-50 DEG C, and stirring for uniformly dissolving; dissolving polylactic acid with the rest water to obtain a polylactic acid solution; heating the materials in the reaction kettle to 70-75 DEG C, dropwise adding the polylactic acid solution, and keeping the temperature for 3-4h after the dropwise adding is finished; and cooling to room temperature so as to obtain the novel reverse-osmosis scale inhibitor. The novel reverse-osmosis scale inhibitor disclosed by the invention has the scale inhibition rate being up to 95%, is small in adding amount, environmentally friendly, stable in property, and long in storage period, and can be used for solving the problems that existing reverse-osmosis inhibitors mainly are foreign products and are limited in treatment capacity, complex in synthesis, relatively high in production cost, and the like in the prior art.